Furthermore, information about the effectiveness and safety of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors for managing diabetes in patients with liver cirrhosis is insufficient [4]. This evidence concerns the gene DPP4 and cirrhosis of liver.